Safety and effectiveness of mail order pharmacy use in diabetes

American Journal of Managed Care

Volumn 19, Issue 11, 2013, Pages 882-887

  Schmittdiel, Julie A ^a   Karter, Andrew J ^a   Dyer, Wendy T ^a   Chan, James ^b   Duru, O Kenrik ^c  

^a DIVISION OF RESEARCH   (United States)

^b Pharmacy Outcomes Research Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; EMERGENCY WARD; FEMALE; HUMAN; LABORATORY TEST; MAIL ORDER PHARMACY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SAFETY; PHARMACY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; EMERGENCY HEALTH SERVICE; POSTAL MAIL; UNITED STATES; UTILIZATION;

AGED; CALIFORNIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; EMERGENCY SERVICE, HOSPITAL; HUMANS; HYPOGLYCEMIC AGENTS; PHARMACEUTICAL SERVICES; POSTAL SERVICE;

EID: 84891359632     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Medel M; for the Pharmaceutical Strategies Group. PBM 101. http:// www.psgconsults.com/resources/pbm-101.pdf. Published 2011. Accessed June 24, 2011.
2. Federal Trade Commission. Pharmacy Benefit Managers: Ownership of Mail-Order Pharmacies. Washington, DC: Federal Trade Commission; 2005.
3. Duru OK, Schmittdiel J, Dyer W, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care. 2010;16(1):33-40.
4. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent health care utilization and cost. Am J Manag Care. 2010;16(8):568-576.
5. Devine S, Vlahiotis A, Sundar H. A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy. J Med Econ. 2010;13(2):203-211.
6. Zhang L, Zakharyan A, Stockl KM, Harada AS, Curtis BS, Solow BK. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. J Med Econ. 2011;14(5):562-567.
7. Schmittdiel J, Karter A, Dyer W, et al. The comparative effectiveness of mail order pharmacy vs. local pharmacy use on LDL-C control in new statin users. J Gen Intern Med. 2011;26(12):1396-1402.
8. Duru OK, Gerzoff RB, Selby JV, et al. Identifying risk factors for racial disparities in diabetes outcomes: the Translating Research Into Action for Diabetes Study. Med Care. 2009;47(6):700-706.
9. Parchman ML, Culler SD. Preventable hospitalizations in primary care shortage areas: an analysis of vulnerable Medicare beneficiaries. Arch Fam Med. 1999;8(6):487-491.
10. Ballard DW, Price M, Fung V, et al. Validation of an algorithm for categorizing the severity of hospital emergency department visits.
11. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium." JAMA. 2010;304(14): 1592-1601.
12. Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectrum. 2002;15(4):240-248.
13. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med. 2005;20(2):1120-1126.
14. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population [published correction appears in JAMA. 2002;288(1):46]. JAMA. 2002;287(19):2519-2527.
15. Kruzikas DT, Jiang HJ, Remus D, et al. Preventable Hospitalizations: A Window Into Primary and Preventive Care, 2000. HCUP Fact Book No. 5. AHRQ Publication No. 04-0056. Agency for Healthcare Research and Quality. http://archive.ahrq.gov/data/hcup/factbk5/. Published September 2004. Accessed December 5, 2011.
16. Moffet HH, Parker MM, SkarKare U, et al. Adherence to laboratory test requests by patients with diabetes: the Diabetes Study of Northern California (DISTANCE). Am J Manag Care. 2011;17(5):339-344.
17. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drugdrug interactions. J Am Pharm Assoc (2003). 2004;44(2):142-151.
18. Messer LC, Laraia BA, Kaufman JS, et al. The development of a standardized neighborhood deprivation index. J Urban Health; 83(6): 1041-1062.
19. Laraia B, Karter AJ, Warton RM, Schillinger D, Moffet HH, Adler N. Place matters: neighborhood deprivation and cardiometabolic risk factors in the Diabetes Study of Northern California (DISTANCE). Soc Sci Med. 2012;74(7):1082-1090.
20. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
21. Rosenbaum PR. Discussion hidden bias in observational studies. Ann Intern Med. 1991;115(11):901-905.
22. Chang VW, Hillier AE, Mehta NK. Neighborhood racial isolation, disorder and obesity. Soc Forces. 2009;87(4):2063-2092.
23. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalizations and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
24. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-2153.
25. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
26. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44(5, pt l): 1640-1661.